NO20073876L - Pyrazolopyrimidinderivater som mGluR2-antagonister - Google Patents

Pyrazolopyrimidinderivater som mGluR2-antagonister

Info

Publication number
NO20073876L
NO20073876L NO20073876A NO20073876A NO20073876L NO 20073876 L NO20073876 L NO 20073876L NO 20073876 A NO20073876 A NO 20073876A NO 20073876 A NO20073876 A NO 20073876A NO 20073876 L NO20073876 L NO 20073876L
Authority
NO
Norway
Prior art keywords
pyrazolopyrimidine derivatives
derivatives
mglur2 antagonists
preparation
treatment
Prior art date
Application number
NO20073876A
Other languages
English (en)
Inventor
Erwin Goetschi
Silvia Gatti Mcarthur
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20073876L publication Critical patent/NO20073876L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår pyrazolopyrimidinderivater med formel (I): hvor R1 til R4 og A er som definert i beskrivelsen, en fremgangsmåte for fremstilling derav, anvendelse av dem for behandling eller forhindring av metabotropisk glutamatreseptormedierte lidelser, anvendelse av dem for fremstilling av medikamenter for behandling av slike lidelser og farmasøytiske preparater inneholdende nevnte derivater.
NO20073876A 2005-02-11 2007-07-24 Pyrazolopyrimidinderivater som mGluR2-antagonister NO20073876L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05101027 2005-02-11
PCT/EP2006/000940 WO2006084634A1 (en) 2005-02-11 2006-02-03 Pyrazolo-pyrimidine derivatives as mglur2 antagonists

Publications (1)

Publication Number Publication Date
NO20073876L true NO20073876L (no) 2007-09-10

Family

ID=36090752

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073876A NO20073876L (no) 2005-02-11 2007-07-24 Pyrazolopyrimidinderivater som mGluR2-antagonister

Country Status (18)

Country Link
US (1) US7361659B2 (no)
EP (1) EP1851225B1 (no)
JP (1) JP4708438B2 (no)
KR (1) KR100968291B1 (no)
CN (1) CN101115755B (no)
AR (1) AR052568A1 (no)
AT (1) ATE512966T1 (no)
AU (1) AU2006212457B2 (no)
BR (1) BRPI0607927A2 (no)
CA (1) CA2597608C (no)
ES (1) ES2365406T3 (no)
IL (1) IL184712A (no)
MX (1) MX2007009106A (no)
NO (1) NO20073876L (no)
RU (1) RU2402553C2 (no)
TW (1) TW200716120A (no)
WO (1) WO2006084634A1 (no)
ZA (1) ZA200706353B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2085398A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2009110901A1 (en) * 2008-03-06 2009-09-11 Sanofi-Aventis Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof as allosteric modulators of mglur
US8207181B2 (en) 2008-03-06 2012-06-26 Sanofi Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof
US20130137865A1 (en) 2010-08-11 2013-05-30 Taisho Pharmaceutical Co., Ltd. Heteroaryl-pyrazole derivative
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
JP6073343B2 (ja) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
CN104736140A (zh) 2012-10-23 2015-06-24 霍夫曼-拉罗奇有限公司 用于治疗自闭症的mGlu2/3拮抗剂
JP2017513844A (ja) 2014-04-23 2017-06-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 知的障害の処置のためのｍＧｌｕ２／３アンタゴニスト
JOP20150179B1 (ar) * 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
EP4406616A3 (en) 2014-11-06 2024-11-06 Bial-R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
US20180185368A1 (en) 2014-11-06 2018-07-05 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
EP3226915B1 (en) 2014-12-03 2019-02-20 Janssen Pharmaceutica NV Radiolabelled mglur2 pet ligands
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
JP6929285B2 (ja) 2015-12-18 2021-09-01 ヤンセン ファーマシューティカ エヌ．ベー． 放射性標識ｍＧｌｕＲ２／３ＰＥＴリガンド
RS60981B1 (sr) 2015-12-18 2020-11-30 Janssen Pharmaceutica Nv Radiooznačeni mglur2/3 pet ligandi
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
AU2017246455B2 (en) * 2016-04-06 2021-09-30 Bial - R&D Investments, S.A. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
KR102530515B1 (ko) 2016-05-05 2023-05-09 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 이미다조[1,2-b]피리다진, 치환된 이미다조[1,5-b]피리다진, 관련 화합물, 및 의학적 장애의 치료에서의 그의 용도
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
EP3566749A4 (en) * 2017-01-09 2020-09-23 Medshine Discovery Inc. THIAZOLE DERIVATIVE AND USES OF IT
WO2019103070A1 (ja) 2017-11-24 2019-05-31 大日本住友製薬株式会社 ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体及びその医薬用途
US11964969B2 (en) 2018-07-06 2024-04-23 Phaeno Therapeutics Co., Ltd Crystal forms of thiazole compound and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU713673B2 (en) 1996-02-07 1999-12-09 Neurocrine Biosciences Inc. Pyrazolopyrimidines as crf receptor antagonists
ATE214704T1 (de) 1997-07-18 2002-04-15 Hoffmann La Roche 5h-thiazolo(3,2-a)pyrimidinderivate
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
CA2442557C (en) * 2001-04-12 2008-12-23 F. Hoffmann-La Roche Ag Dihydro-benzo¬b|¬1,4|diazepin-2-one derivatives as mglur2 antagonists ii
DE602004012083T2 (de) * 2003-04-15 2009-04-23 Astrazeneca Ab Neue Verbindungen, die als Verstärker von Glutamatrezeptoren dienen
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
BRPI0512330A (pt) * 2004-06-21 2008-02-26 Hoffmann La Roche derivados de pirazol-pirimidina

Also Published As

Publication number Publication date
CN101115755B (zh) 2013-01-16
IL184712A0 (en) 2007-12-03
AU2006212457A1 (en) 2006-08-17
JP2008530042A (ja) 2008-08-07
BRPI0607927A2 (pt) 2009-10-20
ES2365406T3 (es) 2011-10-04
ATE512966T1 (de) 2011-07-15
MX2007009106A (es) 2007-09-11
TW200716120A (en) 2007-05-01
IL184712A (en) 2013-05-30
RU2007128624A (ru) 2009-03-20
EP1851225B1 (en) 2011-06-15
WO2006084634A1 (en) 2006-08-17
US7361659B2 (en) 2008-04-22
EP1851225A1 (en) 2007-11-07
AR052568A1 (es) 2007-03-21
CA2597608C (en) 2013-12-24
KR100968291B1 (ko) 2010-07-07
US20060183756A1 (en) 2006-08-17
KR20070104592A (ko) 2007-10-26
JP4708438B2 (ja) 2011-06-22
ZA200706353B (en) 2009-09-30
CN101115755A (zh) 2008-01-30
AU2006212457B2 (en) 2011-04-14
CA2597608A1 (en) 2006-08-17
RU2402553C2 (ru) 2010-10-27

Similar Documents

Publication Publication Date Title
NO20073876L (no) Pyrazolopyrimidinderivater som mGluR2-antagonister
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20092342L (no) Azaspiroderivativater
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20045301L (no) Substituert 1,3-diphenylprop-2-en-1-one derivat, fremstilling og anvendelse derav.
NO20083919L (no) Pyridin- og pyrimidinderivater som mGluR2-antagonister
NO20070339L (no) 1-aza-bicyklo[3 3.1]nonaner
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20071703L (no) Kinazolinderivater
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20062583L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
NO20080408L (no) Azaindazolforbindelser og anvendelse derav
WO2009010871A3 (en) Pyrazole derivatives as antagonists of adenosine a3 receptor
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
NO20062591L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
NO20062923L (no) Nye benzofuranderivater som kan anvendes i forebygging eller behandling av 5-HT6 reseptorrelatert forstyrrelse
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
NO20091766L (no) Spiro-piperidinderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application